TAS4464, a Highly Potent and Selective Inhibitor of NEDD8 Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0644
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

TAS0728, a Covalent-Binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Activity of TAS4464, a Novel NEDD8 Activating Enzyme E1 Inhibitor, Against Multiple Myeloma via Inactivation of NF‐κB Pathways

Cancer Science
Cancer ResearchMedicineOncology
2019English

Rogaratinib: A Potent and Selective Pan-FGFR Inhibitor With Broad Antitumor Activity in FGFR-overexpressing Preclinical Cancer Models

International Journal of Cancer
Cancer ResearchOncology
2019English

CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase With Antitumor Activity in Experimental Models of Human Cancers

Molecular Cancer Therapeutics
Cancer ResearchOncology
2011English

The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Cancer Research
Cancer ResearchOncology
2012English

Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors

Clinical Cancer Research
Cancer ResearchOncology
2018English

Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924

Cancer Cell
Cancer ResearchOncologyCell Biology
2012English

Selective Inhibition of BCL2 Shows Antitumor Effects in Lung Cancer

Cancer Discovery
Oncology
2015English

Pevonedistat, a Nedd8-Activating Enzyme Inhibitor, Sensitizes Neoplastic B-Cells to Death Receptor-Mediated Apoptosis

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy